» Articles » PMID: 36243062

Evidence of Advanced Pulmonary Vascular Remodeling in Obstructive Hypertrophic Cardiomyopathy With Pulmonary Hypertension

Overview
Journal Chest
Publisher Elsevier
Specialty Pulmonary Medicine
Date 2022 Oct 15
PMID 36243062
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Elevated mean pulmonary artery pressure (mPAP) is common in patients with hypertrophic cardiomyopathy (HCM) and heart failure symptoms. However, dynamic left ventricular (LV) outflow tract obstruction may confound interpretation of pulmonary hypertension (PH) pathophysiologic features in HCM when relying on resting invasive hemodynamic data alone.

Research Question: Do structural changes to the lung vasculature clarify PH pathophysiologic features in patients with HCM with progressive heart failure?

Study Design And Methods: Clinical data and ultrarare lung autopsy specimens were acquired retrospectively from the National Institutes of Health (1975-1992). Patients were included based on the availability of lung tissue and recorded mPAP. Discarded tissue from rejected lung donors served as control specimens. Histomorphology was performed on pulmonary arterioles and veins. Comparisons were calculated using the Student t test and Mann-Whitney U test; Pearson correlation was used to assess association between morphometric measurements and HCM cardiac and hemodynamic measurements.

Results: The HCM cohort (n = 7; mean ± SD age, 43 ± 18 years; 71% men) showed maximum mean ± SD LV wall thickness of 25 ± 2.8 mm, mean ± SD outflow tract gradient of 90 ± 30 mm Hg, median mPAP of 25 mm Hg (interquartile range [IQR], 6 mm Hg), median pulmonary artery wedge pressure (PAWP) of 16 mm Hg (IQR, 4 mm Hg), and median pulmonary vascular resistance of 1.8 Wood units (WU; IQR, 2.4 WU). Compared with control samples (n = 5), patients with HCM showed greater indexed pulmonary arterial hypertrophy (20.7 ± 7.2% vs 49.7 ± 12%; P < .001) and arterial wall fibrosis (11.5 ± 3.4 mm vs 21.0 ± 4.7 mm; P < .0001), which correlated with mPAP (r = 0.84; P = .018), PAWP (r = 0.74; P = .05), and LV outflow tract gradient (r = 0.78; P = .035). Compared with control samples, pulmonary vein thickness was increased by 2.9-fold (P = .008) in the HCM group, which correlated with mPAP (r = 0.81; P = .03) and LV outflow tract gradient (r = 0.83; P = .02).

Interpretation: To the best of our knowledge, these data demonstrate for the first time that in patients with obstructive HCM, heart failure is associated with pathogenic pulmonary vascular remodeling even when mPAP is elevated only mildly. These observations clarify PH pathophysiologic features in HCM, with future implications for clinical strategies that mitigate outflow tract obstruction.

Citing Articles

Sex differences in the prevalence and survival of pulmonary hypertension in obstructive hypertrophic cardiomyopathy following septal myectomy.

Nie C, Zhu Y, Xiao M, Zhu C, Meng Y, Lu Z Int J Cardiol Heart Vasc. 2024; 56:101569.

PMID: 39660048 PMC: 11629235. DOI: 10.1016/j.ijcha.2024.101569.


CD8 T cells promote heart failure progression in mice with preexisting left ventricular dysfunction.

Wang D, Weng X, Yue W, Shang L, Wei Y, Clemmer J Front Immunol. 2024; 15:1472133.

PMID: 39324134 PMC: 11422781. DOI: 10.3389/fimmu.2024.1472133.


Pulmonary hypertension associated with left heart disease.

Maron B, Bortman G, De Marco T, Huston J, Lang I, Rosenkranz S Eur Respir J. 2024; 64(4).

PMID: 39209478 PMC: 11525340. DOI: 10.1183/13993003.01344-2024.


Updated Clinical Classification and Hemodynamic Definitions of Pulmonary Hypertension and Its Clinical Implications.

Kularatne M, Gerges C, Jevnikar M, Humbert M, Montani D J Cardiovasc Dev Dis. 2024; 11(3).

PMID: 38535101 PMC: 10971453. DOI: 10.3390/jcdd11030078.


Pulmonary Hypertension: A Contemporary Review.

Johnson S, Sommer N, Cox-Flaherty K, Weissmann N, Ventetuolo C, Maron B Am J Respir Crit Care Med. 2023; 208(5):528-548.

PMID: 37450768 PMC: 10492255. DOI: 10.1164/rccm.202302-0327SO.


References
1.
Delgado J, Conde E, Sanchez V, Lopez-Rios F, Gomez-Sanchez M, Escribano P . Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure. Eur J Heart Fail. 2005; 7(6):1011-6. DOI: 10.1016/j.ejheart.2004.10.021. View

2.
Simonneau G, Montani D, Celermajer D, Denton C, Gatzoulis M, Krowka M . Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2018; 53(1). PMC: 6351336. DOI: 10.1183/13993003.01913-2018. View

3.
Wells S, Rowin E, Boll G, Rastegar H, Wang W, Maron M . Clinical Profile of Nonresponders to Surgical Myectomy with Obstructive Hypertrophic Cardiomyopathy. Am J Med. 2018; 131(6):e235-e239. DOI: 10.1016/j.amjmed.2017.12.031. View

4.
Chetty R, Rose A, Commerford P, Taylor D . Pulmonary veno-occlusive disease associated with hypertrophic cardiomyopathy. Cardiovasc Pathol. 2015; 1(4):289-93. DOI: 10.1016/1054-8807(92)90039-Q. View

5.
Geske J, Konecny T, Ommen S, Nishimura R, Sorajja P, Schaff H . Surgical myectomy improves pulmonary hypertension in obstructive hypertrophic cardiomyopathy. Eur Heart J. 2013; 35(30):2032-9. DOI: 10.1093/eurheartj/eht537. View